Read how new clinical data are driving analyst optimism and investor interest in therapeutics for metabolic dysfunction-associated steatohepatitis.
Key Takeaways
- Leerink initiated coverage and assigned an Outperform rating with a $10 price target
- 1.8 mg dose produced notable triglyceride and total cholesterol reductions alongside weight loss
- Earlier data also indicated liver fibrosis and liver stiffness improvements versus placebo